Powering the age of immune medicine
Adaptive Biotechnologies was founded in 2009 by Chad Robins and Harlan Robins, leveraging research from Fred Hutchinson Cancer Center in Seattle. The company sequences and interprets T-cell and B-cell receptors to detect and monitor disease. Its flagship product clonoSEQ is an FDA-cleared next-generation sequencing test for minimal residual disease (MRD) monitoring in blood cancers. Adaptive went public on Nasdaq in 2019 (ticker: ADPT).
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2019
May 2019
Dec 2009
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
